Expedeon signs supply and license agreement for is Lightning-Link technology
Dr Heikki Lanckriet, CEO and CSO of Expedeon.
The technology will enable Cell Guidance Systems to manufacture TRIFic detection assays on-demand with highly reproducible and scalable results.
Expedeon has signed a supply and license agreement with Cell Guidance Systems, a developer of therapeutic products for medicine and life science research, for use of Expedeon’s proprietary Lightning-Link Rapid Biotin technology in the development and production of TRIFic (Time Resolved Immunofluorescence Exosome Detection Assay) immunoassays. Cell Guidance Systems has already benefitted from the application of Expedeon’s Lightning-Link technology for more than 2 years, and under this new agreement Expedeon becomes preferred immunoreagent supplier to the company
Cell Guidance Systems’ TRIFic rapid detection assay provides quantitative data from purified and unpurified samples, including direct measurements of exosomes in plasma. TRIFic exosome assays are available for widely used markers of exosomes, including the tetraspanin proteins CD9, CD63 and CD81, and provides high sensitivity detection levels which are clear and consistent over a wide range of samples.
The Expedeon Lightning-Link Rapid Biotin kit enables the rapid, direct biotinylation of antibodies, proteins and peptides, or any other biomolecule with an available amine group, with 100% recovery of materials. The kit is optimized for assays in which the biotinylated protein is captured by streptavidin immobilized on a surface. The kit requires only 30 seconds hands-on time and the conjugates are ready to use in under 20 minutes. The technology is fully scalable from 10 ug to 1 g or over, and is stringently QC tested for consistent high quality and excellent batch-to-batch reproducibility.
Using Expedeon’s Lightning-Link biotin technology will enable Cell Guidance Systems to manufacture TRIFic detection assays on-demand with highly reproducible and scalable results. Cell Guidance Systems will benefit from cost savings on detection antibodies and secondary immunoreagents, plus improved production yields and enhanced quality of immunoassay handling.
Dr Heikki Lanckriet, CEO and CSO of Expedeon, commented: “We have been working with Cell Guidance Systems for several years and are delighted to strengthen the relationship. Our technology provides a rapid, easy to use, efficient method of labelling antibodies and we are confident it will serve Cell Guidance Systems very well in the development and production of their TRIFic detection assay kits. This latest agreement follows a number of license and supply agreements with various partners for Lightning-Link, underlining the increasing demand in academia and industry for our proprietary solutions, which help drive the life sciences research sector.”
Dr Laur-Alexandru Botos, Senior Research Scientist at Cell Guidance Systems said: “TRIFic kit is an exquisitely sensitive europium time resolved immunofluorescence assay for exosome markers. The Lightning-Link® Rapid Biotin technology is used to generate stable biotin conjugates as components of this platform. We have found Expedeon’s cutting edge technologies to be reliable and meet the high standards that our customers demand, and will be invaluable in ensuring the TRIFic detection assay kits enable researcher to save time and costs.”
Related News
-
News Swiss pharma industry warns US tariffs could harm global patient care
The Swiss pharmaceutical sector has raised alarms over new US tariffs on medicines, warning of disrupted supply chains, increased costs, and delayed innovation, all of which could jeopardise patient access to essential treatments worldwide.
-
News Women in Pharma: CPHI India – India’s Pharmaceutical Industry and Gender Inclusion Challenges
India’s pharmaceutical industry has emerged as a significant player in the global market, valued at USD 50 billion in FY 2023-2024, according to Frost & Sullivan’s analysis. This sector encompasses a diverse portfolio, including drugs, vacc... -
News Biogen acquires Apellis Pharmaceuticals to boost immunology and rare disease profile
Biogen Inc. has announced its acquisition of Apellis Pharmaceuticals, Inc., a move that is set to significantly enhance its growth portfolio in immunology and rare diseases. The agreement, valued at approximately US$5.6 billion, will see Biogen purchas... -
News Gilead Sciences acquires Ouro Medicines for over US$2 billion
Gilead Sciences confirms a deal to take over Ouro Medicines, adding to a portfolio of therapies for autoimmune diseases.
-
News Women in Pharma: Advancing Women's Health
Discover the latest innovations in technologies and therapeutics that are revolutionising women's health in our latest CPHI Online Women in Pharma infographic.
-
News CPHI Pharma Awards 2026: Recognising Excellence in an Evolving Industry
Submissions now open — deadline May 16
-
News Dr Reddy's to launch generic semaglutide in India
Dr Reddy’s Laboratories, one of India’s leading pharmaceutical companies, is preparing to launch a generic version of semaglutide, branded as Obeda, in March. Obeda is expected to provide a more affordable alternative to Ozempic a... -
News Frontier Biotech and GSK Forge RNA Therapy Partnership
Frontier Biotechnologies and GSK have entered a global licensing agreement to advance small interfering RNA (siRNA) therapeutics. This collaboration grants GSK exclusive rights to develop and commercialise two promising siRNA candidates, marking a mile...